Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 72
13
Diseases
44
Unique genes
0.388
Avg. similarity score
Hemoglobin m disease
Most-connected disease (10 links)
Disease
Searched: methemoglobinemia, alpha type
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
methemoglobinemia, alpha type
Hemoglobin m disease
erythrocytosis, familial, 7
Alpha thalassemia
Hemoglobin barts fetalis syndrome
Hemoglobin h disease
Thalassemia
Unstable hemoglobin disease
Methemoglobinemia
HBA1-related alpha thalassemia spectrum
HBA2-related alpha thalassemia spectrum
Chloracne
Polycythemia vera
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Hemoglobin m disease | 10 | 10 | 3 |
| erythrocytosis, familial, 7 | 10 | 10 | 2 |
| methemoglobinemia, alpha type | 10 | 10 | 2 |
| Alpha thalassemia | 7 | 7 | 3 |
| Hemoglobin barts fetalis syndrome | 7 | 7 | 3 |
| Hemoglobin h disease | 7 | 7 | 3 |
| Thalassemia | 7 | 7 | 5 |
| Unstable hemoglobin disease | 7 | 7 | 3 |
| Methemoglobinemia | 6 | 6 | 6 |
| HBA1-related alpha thalassemia spectrum | 5 | 5 | 1 |
| HBA2-related alpha thalassemia spectrum | 5 | 5 | 1 |
| Chloracne | 4 | 4 | 33 |
| Polycythemia vera | 3 | 3 | 9 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| HBA1 | 12 / 13 | Alpha thalassemia, Chloracne, erythrocytosis, familial, 7, HBA1-related alpha thalassemia spectrum and 8 more |
| HBA2 | 11 / 13 | Alpha thalassemia, Chloracne, erythrocytosis, familial, 7, HBA2-related alpha thalassemia spectrum and 7 more |
| HBB | 6 / 13 | Chloracne, Hemoglobin m disease, Methemoglobinemia, Polycythemia vera and 2 more |
| ATRX | 3 / 13 | Alpha thalassemia, Hemoglobin barts fetalis syndrome, Hemoglobin h disease |
| GSTM1 | 2 / 13 | Chloracne, Thalassemia |
| HBD | 2 / 13 | Chloracne, Thalassemia |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Erythrocytes take up oxygen and release carbon dioxide | Reactome | 3 / 9 | 91.0× | 3.80e-6 | 1.63e-4 ✓ sig. |
| Scavenging of heme from plasma | Reactome | 3 / 13 | 63.0× | 1.28e-5 | 4.35e-4 ✓ sig. |
| Erythrocytes take up carbon dioxide and release oxygen | Reactome | 3 / 13 | 63.0× | 1.28e-5 | 4.35e-4 ✓ sig. |
| Pathways in cancer | KEGG | 10 / 533 | 5.1× | 1.73e-5 | 5.58e-4 ✓ sig. |
| Factors involved in megakaryocyte development and platelet production | Reactome | 5 / 99 | 13.8× | 2.89e-5 | 8.55e-4 ✓ sig. |
| Malaria | KEGG | 4 / 50 | 21.8× | 3.19e-5 | 9.25e-4 ✓ sig. |
| Measles | KEGG | 5 / 139 | 9.8× | 1.46e-4 | 3.12e-3 ✓ sig. |
| African trypanosomiasis | KEGG | 3 / 37 | 22.1× | 3.27e-4 | 5.92e-3 ✓ sig. |
| Small cell lung cancer | KEGG | 4 / 93 | 11.7× | 3.61e-4 | 6.42e-3 ✓ sig. |
| Vitamin C (ascorbate) metabolism | Reactome | 2 / 8 | 68.2× | 3.62e-4 | 6.43e-3 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 5 / 170 | 8.0× | 3.72e-4 | 6.57e-3 ✓ sig. |
| Influenza A | KEGG | 5 / 173 | 7.9× | 4.03e-4 | 7.00e-3 ✓ sig. |
| Cyclin D associated events in G1 | Reactome | 3 / 44 | 18.6× | 5.47e-4 | 8.86e-3 ✓ sig. |
| Epstein-Barr virus infection | KEGG | 5 / 204 | 6.7× | 8.53e-4 | 1.24e-2 ✓ sig. |
| Chemical carcinogenesis - receptor activation | KEGG | 5 / 215 | 6.3× | 1.08e-3 | 1.49e-2 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| carbon dioxide transport | GO:0015670 | 5 / 13 | 163× | 7.26e-11 | 2.19e-8 ✓ sig. |
| oxygen transport | GO:0015671 | 5 / 17 | 125× | 3.47e-10 | 8.79e-8 ✓ sig. |
| erythrocyte development | GO:0048821 | 5 / 32 | 66.4× | 1.10e-8 | 1.84e-6 ✓ sig. |
| nitric oxide transport | GO:0030185 | 3 / 5 | 255× | 1.21e-7 | 1.45e-5 ✓ sig. |
| hydrogen peroxide catabolic process | GO:0042744 | 3 / 21 | 60.7× | 1.57e-5 | 7.70e-4 ✓ sig. |
| nitrobenzene metabolic process | GO:0018916 | 2 / 4 | 212× | 3.24e-5 | 1.34e-3 ✓ sig. |
| xenobiotic catabolic process | GO:0042178 | 3 / 28 | 45.5× | 3.83e-5 | 1.52e-3 ✓ sig. |
| cellular detoxification of nitrogen compound | GO:0070458 | 2 / 5 | 170× | 5.39e-5 | 1.97e-3 ✓ sig. |
| regulation of peptidyl-tyrosine phosphorylation | GO:0050730 | 2 / 6 | 142× | 8.08e-5 | 2.68e-3 ✓ sig. |
| inflammatory response | GO:0006954 | 7 / 467 | 6.4× | 1.00e-4 | 3.14e-3 ✓ sig. |
| response to hydrogen peroxide | GO:0042542 | 3 / 39 | 32.7× | 1.05e-4 | 3.24e-3 ✓ sig. |
| positive regulation of nitric oxide biosynthetic process | GO:0045429 | 3 / 42 | 30.3× | 1.31e-4 | 3.82e-3 ✓ sig. |
| positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction | GO:0051897 | 5 / 217 | 9.8× | 1.51e-4 | 4.26e-3 ✓ sig. |
| regulation of nitric oxide biosynthetic process | GO:0045428 | 2 / 10 | 84.9× | 2.41e-4 | 5.95e-3 ✓ sig. |
| immune response | GO:0006955 | 7 / 543 | 5.5× | 2.54e-4 | 6.16e-3 ✓ sig. |